These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. To be drug or prodrug: structure-property exploratory approach regarding oral bioavailability. Damião MC; Pasqualoto KF; Polli MC; Parise Filho R J Pharm Pharm Sci; 2014; 17(4):532-40. PubMed ID: 25579432 [TBL] [Abstract][Full Text] [Related]
3. Strategies to improve oral drug bioavailability. Gomez-Orellana I Expert Opin Drug Deliv; 2005 May; 2(3):419-33. PubMed ID: 16296764 [TBL] [Abstract][Full Text] [Related]
4. Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist. Beaumont K; Webster R; Gardner I; Dack K Curr Drug Metab; 2003 Dec; 4(6):461-85. PubMed ID: 14683475 [TBL] [Abstract][Full Text] [Related]
5. Ask the experts: past, present and future of the rule of five. Baell J; Congreve M; Leeson P; Abad-Zapatero C Future Med Chem; 2013 May; 5(7):745-52. PubMed ID: 23651089 [TBL] [Abstract][Full Text] [Related]
6. Analysis of the Physicochemical Properties of Acaricides Based on Lipinski's Rule of Five. Chen X; Li H; Tian L; Li Q; Luo J; Zhang Y J Comput Biol; 2020 Sep; 27(9):1397-1406. PubMed ID: 32031890 [TBL] [Abstract][Full Text] [Related]
7. Drug-likeness and increased hydrophobicity of commercially available compound libraries for drug screening. Zuegg J; Cooper MA Curr Top Med Chem; 2012; 12(14):1500-13. PubMed ID: 22827520 [TBL] [Abstract][Full Text] [Related]
8. Absorption matters: A closer look at popular oral bioavailability rules for drug approvals. Caminero Gomes Soares A; Marques Sousa GH; Calil RL; Goulart Trossini GH Mol Inform; 2023 Nov; 42(11):e202300115. PubMed ID: 37550251 [TBL] [Abstract][Full Text] [Related]
9. Amorphous Solid Dispersions or Prodrugs: Complementary Strategies to Increase Drug Absorption. Rumondor ACF; Dhareshwar SS; Kesisoglou F J Pharm Sci; 2016 Sep; 105(9):2498-2508. PubMed ID: 26886316 [TBL] [Abstract][Full Text] [Related]
10. Prodrug approaches for enhancing the bioavailability of drugs with low solubility. Müller CE Chem Biodivers; 2009 Nov; 6(11):2071-83. PubMed ID: 19937841 [TBL] [Abstract][Full Text] [Related]
11. Diverse approaches for the enhancement of oral drug bioavailability. Fasinu P; Pillay V; Ndesendo VM; du Toit LC; Choonara YE Biopharm Drug Dispos; 2011 May; 32(4):185-209. PubMed ID: 21480294 [TBL] [Abstract][Full Text] [Related]
12. Targeted prodrug design to optimize drug delivery. Han HK; Amidon GL AAPS PharmSci; 2000; 2(1):E6. PubMed ID: 11741222 [TBL] [Abstract][Full Text] [Related]
13. Development of water-soluble prodrugs of the HIV-1 protease inhibitor KNI-727: importance of the conversion time for higher gastrointestinal absorption of prodrugs based on spontaneous chemical cleavage. Sohma Y; Hayashi Y; Ito T; Matsumoto H; Kimura T; Kiso Y J Med Chem; 2003 Sep; 46(19):4124-35. PubMed ID: 12954064 [TBL] [Abstract][Full Text] [Related]
15. A novel strategy for ADME screening of prodrugs: combined use of serum and hepatocytes to integrate bioactivation and clearance, and predict exposure to both active and prodrug to the systemic circulation. Hoppe E; Hewitt NJ; Buchstaller HP; Eggenweiler HM; Sirrenberg C; Zimmermann A; März J; Schwartz H; Saal C; Meyring M; Hecht S J Pharm Sci; 2014 May; 103(5):1504-14. PubMed ID: 24648352 [TBL] [Abstract][Full Text] [Related]
19. Is prodrug design an approach to increase water solubility? Sanches BMA; Ferreira EI Int J Pharm; 2019 Sep; 568():118498. PubMed ID: 31301465 [TBL] [Abstract][Full Text] [Related]
20. Prodrug approaches for CNS delivery. Rautio J; Laine K; Gynther M; Savolainen J AAPS J; 2008; 10(1):92-102. PubMed ID: 18446509 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]